Healthcare AI Just Entered a New Era: What CMS’s Proposed Rule Could Mean

The conversation around healthcare AI changed dramatically last week.

For the first time, CMS has proposed dedicated reimbursement pathways for select AI-enabled medical services, signaling that artificial intelligence is moving beyond a technology investment and toward becoming a reimbursable component of clinical care. While this remains a proposed rule and is still open for public comment, the direction is significant and could reshape how healthcare organizations evaluate, implement, and govern AI.

In this week’s episode, Douglas Flora, MD, LSSBB, Sanjay Juneja, M.D., and healthcare attorney Jordan Johnson, MSHA, M.Jur/MLS discuss what this proposal really means for healthcare organizations, AI companies, investors, and clinical leaders.

Some of the topics explored include:

• Why reimbursement changes the economics of healthcare AI.
• How AI companies will increasingly compete on clinical evidence—not just algorithms.
• Why governance, documentation, and outcomes are becoming competitive advantages.
• How CMS reimbursement could influence commercial payer adoption.
• What healthcare organizations should be doing now while the rule is still in the proposal stage.

One message stood out throughout the discussion:

Accuracy gets you FDA clearance. Evidence gets you reimbursement. Documentation gets you paid. Governance keeps you trusted.

Whether you’re a healthcare executive, physician, AI developer, investor, or policy leader, this episode provides practical insight into one of the most important regulatory developments affecting healthcare innovation today.

🎥 Watch the full episode:

▶️ Watch the episode preview:

As always, we’d love to hear your thoughts. How do you see AI reimbursement changing the future of healthcare? Join the conversation and let us know.